Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
BLISS GVS PHARMA faces its most acute risk from perfect (10.0/10) compliance scoring, indicating material gaps in BRSR Core Expansion disclosures—non-compliance exposes the company to SEBI enforcement action and potential delisting despite its ₹667.2 crore revenue scale. Extended Producer Responsibility (EPR) exposure remains unquantified (Unknown applicability status), creating contingent liability risk that could range ₹1–4 crore annually once regulatory clarity emerges on pharmaceutical packaging classifications. The company's reported zero Scope 1 and 2 emissions data lacks credibility for a manufacturing pharma operator, suggesting measurement or disclosure gaps that amplify compliance risk and mask true climate cost exposure under India's emerging carbon pricing framework (₹600–900/tonne). Immediate priorities: audit BRSR disclosure completeness, clarify EPR applicability for drug formulations/packaging, and establish verified emissions baseline to avoid regulatory scrutiny and reputational damage.
Source: BLISS GVS PHARMA LIMITED BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.